Replies to post #3548 on Halozyme Therapeutics Inc (HALO)

[maumar]

I listened to part of the Roche conference call. About 14 minutes into the call - I'm not quoting exactly - "Herceptin SC is progressing very well… in the 29 markets launched, Herceptin SC has a 20% overall share, in some markets shares of above 50% at a very early stage of the launch."

Can anybody compare this with what they released last quarter? I don't know if they said anything about Mabthera SC.

Has anybody listened to the Baxter call?